From a Phase 2 TB Vaccine Trial, to Early Work to Neutralize Drug-Resistant Malaria, $10.7 Million in New Investments from GHIT Fund Escalates and Diversifies Japan's Global Health Commitments Projects advance product development partnerships with Japanese pharma, Kickstart GHIT's Grand Challenges; New funds also target dengue, leishmaniasis

TOKYO, Nov. 4, 2015 /PRNewswire-USNewswire/ -- The Global Health Innovative Technology Fund (GHIT Fund), which in the last two years has invested US$43 million to develop innovative tools for fighting diseases worldwide, today announced it is investing $10.7 million* at multiple points in the product development pipeline to seek new interventions for malaria, tuberculosis (TB), leishmaniasis and dengue. The projects come at a crucial time for all four diseases: new drugs and vaccines for TB and malaria are desperately needed to fight rising resistance to existing therapies, while dengue infections continue to mount worldwide—and with no drugs or vaccines yet on the market to treat or...